Catalent sees Q1 revenue $982M, consensus $939.14M.

Catalent announced preliminary financial results for the Q1. Sees Q1 net revenue, excluding COVID revenue of ~$185M;Q1’24 net loss of ($715M), includes non-cash goodwill impairment charges of $700M; and Adjusted EBITDA of $115M decreased 38% as reported, or 39% in constant currency, compared to Q1’23. “As Catalent continues to execute our strategy to enhance value for our stakeholders, the strength of our internal pipeline and our solid first quarter financial performance give us the confidence to reiterate our guidance for the full year,” said Alessandro Maselli, President and CEO of Catalent “We continue to make strides towards improving our operations and bringing our performance back to pre-COVID levels. We remain the partner of choice for our customers’ most complex manufacturing needs and continue to work to complete strategic capital investments that will address the surging demand from patients in high-growth areas, including capacity for sterile pre-filled syringes.”